Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 265.00
Bid: 260.00
Ask: 270.00
Change: 15.00 (6.00%)
Spread: 10.00 (3.846%)
Open: 253.00
High: 270.00
Low: 255.00
Prev. Close: 250.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Tungsten West 'largest Western tungsten producer'

Mon, 16th Jan 2023 16:26

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Aterian PLC - Morocco-focused metal exploration and development company - Identifies several new high-priority geophysical anomalies at its 100%-owned Agdz copper and silver project. Increases the target area due for further exploration. Chair Charles Bray says: "We are currently working towards building a conceptual geological model for the project, which has already demonstrated some excellent high-grade copper and silver values, up to 26.5% copper and 448 grams per tonne of silver. The presence of multiple historical copper workings at Agdz provides further encouragement, with the project located in an established copper and silver mining district in the eastern Anti-Atlas of Morocco and is an additional exciting exploration opportunity in our Moroccan portfolio."

----------

Quadrise Fuels International PLC - London-based energy solutions provider for a cleaner planet - Says bioMSAR fuel arrived at it client site in Morocco during December. The fuel is currently at Moroccan customs, awaiting final clearance. Expects the remaining logistical issues will be resolved this month so that the trial can then proceed as planned. Expects a successful trial to follow via discussions to conclude a commercial fuel supply agreement in the first half of 2023 as planned. Also announces commercial discussions for licence supply in Utah, US, progressing well, working towards execution of definitive agreements by the first quarter of 2023. Chief Executive Officer Jason Miles says: "Whilst we are frustrated with the delays that we have faced in progressing some of our projects, we remain confident that these will be overcome soon. The team has worked extremely diligently to seek to navigate these challenges such that the impact on the delivery of our projects should be minimal."

----------

Poolbeg Pharma PLC - London-based biopharmaceutical company focusing on infectious diseases - Files patent application to protect use of POLB 001 for new oncology indication. Says scientific finding indicate POLB 001 has the potential to dampen the pro-inflammatory cytokine release syndrome affecting patients receiving CAR T cell therapies. Submits a patent application for the use of POLB 001 to treat CRS in CAR T cell patients. Says it is progressing towards trial initiation in 2024. Scientific advisory board member Brendan Buckley says: "By reducing runaway inflammation associated with CRS, POLB 001 has the potential to significantly reduce the serious adverse effects that many CAR T cell patients suffer. With 18 to 19 million cases of cancer diagnosed globally each year, the use of cell therapies is predicted to expand significantly over the coming years with the CAR T cell market expected to grow to an estimated USD6 billion by 2031...we look forward to updating the market as to the progress of this exciting programme."

----------

Coro Energy PLC - Leeds, England-based energy company with a natural gas and clean energy portfolio - Says production from its Italian portfolio continued in line with expectations during the fourth quarter of 2022, following record quarterly revenues in the preceding quarter. Revenue is EUR1.5 million in the fourth quarter, down from EUR2.0 million in the third quarter, and marginally down from EUR1.6 million in the second quarter. Says 1.4 million standard cubic metres of natural gas were produced during the fourth quarter, up from 1.2 million in the third quarter, but down from 1.6 million in the second quarter. Full year 2022 natural gas production is 5.1 million standard cubic metres and revenue is EUR6.0 million. In the week ended January 8, Italian portfolio production averaged 21,091 standard cubic metres per day, up 50% from the 2022 annual average of 13,979 standard cubic metres per day.

----------

Upland Resources Ltd - Malaysia-focused upstream oil and gas company - Believes it is "unequally positioned" in Sarawak, Malaysia, providing the December workflow update on the SK334 joint technical study activity. Says time and resources spent in adding value to the Sarawak SK334 JTS workstream has the potential to generate "significant returns" to shareholders. Chair & Chief Executive Officer Bolhassan Di says: "Block SK334 in Sarawak offers transformational potential for a company our size, sedimentary basins in Sarawak are proven prolific hydrocarbons bearing basins. We are encouraged by the continuing recent discoveries in surrounding blocks...Separately, we also recognise the potential emerging from our UK North Sea P2478 Dunrobin prospect and are working closely with the joint venture partners to realise value there as technical studies complete."

----------

Bradda Head Lithium Ltd - North America-focused lithium development group - Says updated mineral resource estimate at its Basin East project in the US state of Arizona has increased by 17%, alongside a 22% increase in tonnes contained lithium carbonate equivalent, based on "only" 1,200 metres of drilling. Says the 2022 drilling programme has given the company "great confidence" in the estimate at Basin East. Chief Executive Officer Charles FitzRoy says: "2023 is going to be an exciting year of resource growth for Bradda Head. With more drilling already planned at Basin East Extension and Basin North, Bradda Head is excellently placed to take full advantage of the near-term resource growth potential at our sedimentary lithium assets in Arizona."

----------

Tungsten West PLC - Mining company focused on restarting production at the Hemerdon tungsten and tin mine in Devon, England - Says post-tax net present value is GBP297 million with an internal rate of return of 25%. Projects Hemerdon average annual production to be 2,900 tonnes of tungsten trioxide in concentrate and 310 tonnes of tin in concentrate. Says life of mine is 27 years with an an annual average steady-state mining rate of 3.5 megatonnes per annum. Says LOM post financing free cash flow is GBP550 million. Believes feasibility study shows company could be the largest Western tungsten producer. Says GBP12 million of capital expenditure already spent, with remaining capex being GBP31.1 million as of October 1. Executive Vice Chair Mark Thompson says: "The feasibility study provides solutions to the energy price challenges and will enable increased operating efficiencies at the project...Tungsten is on both the EU and US lists of critical metals and due to geopolitical tensions and security of supply issues the market remains strong. With Hemerdon in production, we will provide an alternative source of tungsten to Western consumers in markets which are otherwise dominated by China."

----------

ICG-Longbow Senior Secured UK Property Debt Investments Ltd - Guernsey-based investment company with a portfolio of UK real estate debt investments - Receives remaining GBP6.5 million balance of its LBS loan alongside GBP300,000 in interest and fees, following a refinancing of the underlying property. Says the repayment allows the company to continue its programme of capital distributions to shareholders.

----------

Faron Pharmaceuticals Ltd - Turku, Finland-based biopharmaceutical company focusing on difficult-to-treat cancers and inflammation via precision immunotherapy - Reports encouraging additional data for bexmarilimab for the treatment of hematological malignancies. Says it provoked objective responses in 3 out of 5 patients doesed in the first doublet cohort of the phase 1 and 2 Bexmab study. Says study showed rapid enrolment in doublet and triplet combinations. "The additional BEXMAB data indicates that bexmarilimab contributed to positive responses in the refractory setting where patients failed standard of care," says Chief Medical Officer Marie-Louise Fjallskog. "We are excited about the initial promising results and look forward to gathering additional clinical data for more robust read-outs."

----------

ACP Energy PLC - Lutterworth, England-based company looking for value-accretive opportunities in the oil and gas industry - Says shares are suspended as it signs a sale and purchase agreement for an equity interest being sold by Vinncler CA. Vinncler own the producing assets of a "highly prolific" basin in Latin America currently producing around 4,100 barrels per day, says ACP Energy. Says the proposed acquisition is in line with ACP Energy's stated strategy of identifying and acquiring hydrocarbon producing assets that are either in production or near to production. Says the proposed acquisition, if completed, will constitute a reverse takeover.

----------

By Greg Rosenvinge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
13 Mar 2024 20:49

EARNINGS AND TRADING: PensionBee nears profit; OptiBiotix Indian deal

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
13 Mar 2024 11:52

Faron Pharmaceuticals reports year of clinical progress

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals reported a year of strong progress on Wednesday, with significant overall response rates seen in both previously hypomethylating agent (HMA)-failed and higher-risk myelodysplastic syndrome (MDS) patient populations in the phase one part of the BEXMAB study.

Read more
6 Mar 2024 16:06

UK earnings, trading statements calendar - next 7 days

Thursday 7 March 
Admiral Group PLCFull Year Results
Aviva PLCFull Year Results
Beazley PLCFull Year Results
Brooks Macdonald Group PLCHalf Year Results
Coats Group PLCFull Year Results
Darktrace PLCHalf Year Results
Elementis PLCFull Year Results
Entain PLCFull Year Results
Funding Circle Holdings PLCFull Year Results
Harbour Energy PLCFull Year Results
ITV PLCFull Year Results
Kier Group PLCFull Year Results
Melrose Industries PLCFull Year Results
Nexus Infrastructure PLCFull Year Results
PageGroup PLCFull Year Results
Physiomics PLCHalf Year Results
Rentokil Initial PLCFull Year Results
Robert Walters PLCFull Year Results
Spirax-Sarco Engineering PLCFull Year Results
TT Electronics PLCFull Year Results
Tyman PLCFull Year Results
Friday 8 March 
Informa PLCFull Year Results
Just Group PLCFull Year Results
LMS Capital PLCFull Year Results
Stelrad Group PLCFull Year Results
Monday 11 March 
HgCapital Trust PLCFull Year Results
Mincon Group PLCFull Year Results
MTI Wireless Edge LtdFull Year Results
Tuesday 12 March 
BATM Advanced Communications LtdFull Year Results
Costain Group PLCFull Year Results
Domino's Pizza Group PLCFull Year Results
Fonix Mobile PLCHalf Year Results
Foresight Solar Fund LtdFull Year Results
Genuit PLCFull Year Results
H&T Group PLCFull Year Results
Hill & Smith PLCFull Year Results
MaxCyte IncFull Year Results
Persimmon PLCFull Year Results
Synthomer PLCFull Year Results
Target Healthcare REIT PLCHalf Year Results
TI Fluid Systems PLCFull Year Results
TP ICAP Group PLCFull Year Results
Wednesday 13 March 
4imprint Group PLCFull Year Results
Advanced Medical Solutions Group PLCFull Year Results
Balfour Beatty PLCFull Year Results
Centaur Media PLCFull Year Results
Faron Pharmaceuticals LtdFull Year Results
Ferrexpo PLCFull Year Results
Gym Group PLCFull Year Results
Hochschild Mining PLCFull Year Results
IP Group PLCFull Year Results
Keywords Studios PLCFull Year Results
Kin & Carta PLCHalf Year Results
Metro Bank Holdings PLCFull Year Results
Nexteq PLCFull Year Results
PensionBee Group PLCFull Year Results
Public Policy Holding Co IncFull Year Results
Seraphim Space Investment Trust PLCHalf Year Results
Supermarket Income REIT PLCHalf Year Results
Trainline PLCTrading Statement
Vaalco Energy IncFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.

Read more
4 Mar 2024 19:59

TRADING UPDATES: Beowulf raises funds for Kallak iron ore project

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
4 Mar 2024 10:40

Faron Pharmaceuticals shores up cash with EUR 3.2m convertible loans

(Sharecast News) - Faron Pharmaceuticals announced on Monday that it has successfully secured binding commitments for convertible loans totalling €3.2m from a select group of existing shareholders.

Read more
27 Feb 2024 21:12

TRADING UPDATES: Armadale Capital eyes Mahenge project financing

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
22 Feb 2024 14:26

UK earnings, trading statements calendar - next 7 days

Friday 23 February 
City of London Investment Group PLCHalf Year Results
Irish Residential Properties REIT PLCFull Year Results
Standard Chartered PLCFull Year Results
Monday 26 February 
Base Resources LtdHalf Year Results
Bunzl PLCFull Year Results
EnSilica PLCHalf Year Results
Kosmos Energy LtdFull Year Results
Made Tech Group PLCHalf Year Results
Tristel PLCHalf Year Results
Tuesday 27 February 
abrdn Equity Income Trust PLCFull Year Results
abrdn PLCFull Year Results
Croda International PLCFull Year Results
Kitwave Group PLCFull Year Results
McBride PLCHalf Year Results
PCI-PAL PLCHalf Year Results
Smith & Nephew PLCFull Year Results
Synectics PLCFull Year Results
Uniphar PLCFull Year Results
Unite Group PLCFull Year Results
Wednesday 28 February 
AB Dynamics PLCTrading Statement
ASA International Group PLCTrading Statement
Aston Martin Lagonda Global Holdings PLCFull Year Results
Avingtrans PLCHalf Year Results
Bluefield Solar Income Fund LtdHalf Year Results
Derwent London PLCFull Year Results
Glenveagh Properties PLCFull Year Results
Grit Real Estate Income Group LtdHalf Year Results
Harmony Energy Income Trust PLCFull Year Results
Hutchmed China LtdFull Year Results
International Personal Finance PLCFull Year Results
Just Eat Takeaway.com NVFull Year Results
Primary Health Properties PLCFull Year Results
Reckitt Benckiser Group PLCFull Year Results
Renewables Infrastructure Group LtdFull Year Results
RHI Magnesita NVFull Year Results
St James's Place PLCFull Year Results
Taylor Wimpey PLCFull Year Results
Thursday 29 February 
Cairn Homes PLCFull Year Results
CVS Group PLCFull Year Results
Drax Group PLCFull Year Results
Faron Pharmaceuticals LtdFull Year Results
Haleon PLCFull Year Results
Hammerson PLCFull Year Results
Howden Joinery Group PLCFull Year Results
Hunting PLCFull Year Results
International Biotechnology Trust PLCFull Year Results
London Stock Exchange Group PLCFull Year Results
Macfarlane Group PLCFull Year Results
Man Group PLCFull Year Results
Mobico Group PLCFull Year Results
Nexus Infrastructure PLCFull Year Results
Ocado Group PLCFull Year Results
PPHE Hotel Group LtdFull Year Results
Schroder Oriental Income Fund LtdFull Year Results
Schroders PLCFull Year Results
Serco Group PLCFull Year Results
Shaftesbury Capital PLCFull Year Results
Spectris PLCFull Year Results
Spire Healthcare Group PLCFull Year Results
Vesuvius PLCFull Year Results
Weir Group PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
19 Feb 2024 11:23

Faron discloses events of default on debt obligations to lender

(Alliance News) - Faron Pharmaceuticals Ltd shares fell on Monday, after it said it is in breach of several undertakings agreed in a secured debt deal with lender IPF Fund II SCA, SICAV-FIAR.

Read more
25 Jan 2024 20:09

TRADING UPDATES: Microsaic completes acquisition; Narf revenue soars

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
9 Jan 2024 12:36

Faron launches second phase of leukaemia treatment trial

(Sharecast News) - Faron Pharmaceuticals has initiated phase two of the BEXMAB trial, it announced on Tuesday, marking a significant milestone in its cancer treatment development programme.

Read more
9 Jan 2024 10:56

Faron says first patient dosed in phase two Bexmab trial for cancer

(Alliance News) - Faron Pharmaceuticals Ltd on Tuesday announced that the first patient has been dosed in phase 2 of its Bexmab trial.

Read more
11 Dec 2023 13:22

Faron unveils promising antibody study results

(Sharecast News) - Faron Pharmaceuticals unveiled promising phase one data from its BEXMAB study in myeloid malignancies during the 65th American Society of Hematology (ASH) annual meeting, it announced on Monday.

Read more
11 Dec 2023 12:01

Faron Pharmaceuticals hails positive results of cancer drug trial

(Alliance News) - Faron Pharmaceuticals Ltd on Monday said results from a probe of a cancer drug were promising.

Read more
7 Dec 2023 19:33

IN BRIEF: Faron Pharma celebrates publication of bexmarilimab results

Faron Pharmaceuticals Ltd - Finland-based clinical-stage biopharmaceutical company - Says that results from its Phase 1/2 MATINS trial of bexmarilimab have been published in Cell Reports Medicine, an open-access journal. According to the trial, bexmarilimab monotherapy shows efficacy in achieving disease control and prolonged survival in late-stage metastatic solid tumours. It also showed that CLEVER-1 targeting is safe and well-tolerated with no serious adverse effects, and that bexmarilimab induced macrophage activation and increased IFNy signalling in patients who achieved disease control and prolonged survival.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.